BERG Forms Research Collaboration with AstraZeneca

BERG, a biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced a research collaboration with
AstraZeneca to identify and evaluate novel targets and therapeutics to treat neurological disorders such as Parkinson’s disease.